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ABSTRACT: Analyzing lipid composition and distribution
within the brain is important to study white matter pathologies
that present focal demyelination lesions, such as multiple
sclerosis. Some lesions can endogenously re-form myelin
sheaths. Therapies aim to enhance this repair process in order
to reduce neurodegeneration and disability progression in
patients. In this context, a lipidomic analysis providing both
precise molecular classiﬁcation and well-deﬁned localization is
crucial to detect changes in myelin lipid content. Here we
develop a correlated heterospectral lipidomic (HSL) approach
based on coregistered Raman spectroscopy, desorption electrospray ionization mass spectrometry (DESI-MS), and
immunoﬂuorescence imaging. We employ HSL to study the structural and compositional lipid proﬁle of demyelination and
remyelination in an induced focal demyelination mouse model and in multiple sclerosis lesions from patients ex vivo. Pixelwise
coregistration of Raman spectroscopy and DESI-MS imaging generated a heterospectral map used to interrelate biomolecular
structure and composition of myelin. Multivariate regression analysis enabled Raman-based assessment of highly speciﬁc lipid
subtypes in complex tissue for the ﬁrst time. This method revealed the temporal dynamics of remyelination and provided the ﬁrst
indication that newly formed myelin has a diﬀerent lipid composition compared to normal myelin. HSL enables detailed
molecular myelin characterization that can substantially improve upon the current understanding of remyelination in multiple
sclerosis and provides a strategy to assess remyelination treatments in animal models.
■ INTRODUCTION
Multiple sclerosis is a degenerative condition of the central
nervous system, characterized by multifocal inﬂammatory
demyelinating lesions. Demyelination of axons compromises
the eﬃciency of saltatory conduction of electrical impulses1 and
reduces metabolic support2,3 to the underlying axon, causing
increased susceptibility to degeneration.4,5 Remyelination
occurs to some extent in many multiple sclerosis lesions, but
this process varies between individual lesions and diﬀerent
patients and over the disease course,6−9 and remyelination
inevitably fails over time.6 Much research is now focusing on
the discovery of therapies that enhance remyelination, aiming
to reduce axonal degeneration and the subsequent progressive
accumulation of disability in patients.
To ﬁnd an eﬀective pro-remyelinating therapy, it will be
crucial to reliably and quickly analyze the amount of
myelination in diﬀerent lesions at the molecular level in animal
models of demyelination and remyelination and, ideally, in
living multiple sclerosis patients. Furthermore, it is important to
distinguish between myelin that has been replaced (remyeli-
nated myelin) and normal myelin. Currently, to detect and
quantify remyelination in tissue samples, whether from animal
models or multiple sclerosis patient brain tissue samples,
researchers generally use histochemical staining (e.g., Luxol fast
blue staining), or immunohistochemistry using antibodies
targeted against myelin proteins such as myelin basic protein
(MBP), or proteolipid protein,10 but do not assess lipids which
are the main component of myelin. The current gold standard
for more comprehensive quantiﬁcation of remyelination in a
lesion, especially in animal models of demyelination, is to use
electron microscopy to directly observe the number of
myelinated axons and myelin sheath thickness, as remyelinated
myelin is usually thinner than normal myelin.11,12 This method,
however, does not examine the molecular content. In general,
conventional methods for assessing myelin require destructive
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sample preparation (e.g., ﬁxation, antigen retrieval, or
delipidation for antibody staining) and are poor at assessing
the lipid composition of myelin.
Therefore, most myelin characterization performed so far has
focused on myelin proteins, rather than on the lipid
components. We know that changes in myelin protein
composition negatively impact axonal survival13,14 and that
subtle changes in protein composition (e.g., Claudin-11) may
occur in myelin after remyelination which may be similar to
that occurring in aging myelin.15 As these proteins are
membrane bound or lipid anchored, alterations in the lipid
composition of myelin in disease or repair may also be
important. However, as yet, we have not identiﬁed any studies
addressing the lipid composition of newly formed myelin after
demyelination in either models or humans, perhaps as it is
extremely challenging to identify spatially resolved lipids in a
focal lesion with current techniques. Yet, a full lipidomic
characterization of myelin and remyelinated myelin may
provide additional information to help better understand
diseases such as multiple sclerosis.
In recent years, several optical techniques have been
introduced for myelin characterization such as Fourier
transform infrared spectroscopy16,17 as well as stimulated
Raman spectroscopy and coherent anti-Stokes Raman spec-
troscopy.18,19 Spontaneous Raman spectroscopy techniques can
acquire the full complement of biomolecular vibrational
information and identify a wealth of biomolecules (i.e., speciﬁc
biomolecular structures and conformations of proteins, lipids,
nucleic acids, etc.) in tissue, without labeling, using endogenous
molecules as a contrast mechanism. Importantly, lipids are the
major components in myelin sheaths, and these are particularly
strong Raman scatterers, making this vibrational imaging
technique uniquely suited to elucidate the complex structure
of myelin.19,20 Since Raman spectroscopy is nondestructive and
requires no tissue processing, it can combine with other
complementary techniques such as mass spectrometric (MS)
surface analysis by secondary ion MS (SIMS), desorption
electrospray ionization (DESI) or matrix-assisted laser
desorption−ionization MS (MALDI).21−23 While Raman
spectroscopy provides vibrational structural information, mass
spectrometry enables molecular identiﬁcation. Although several
studies have reported on both techniques, their heterospectral
analysis has not yet been realized, mainly due to the
computational complexity associated with coregistration of
the hyperspectral data sets. Recently, a partial correlative
approach was developed for Raman spectroscopy and MALDI
using neighboring tissue sections as a new analytical strategy.24
While MALDI provides information on a broad range of
species from metabolites to proteins, it requires substantial
sample preparation and presents limited capabilities in the
detection and characterization of species in the low m/z region
associated with lipids.25 In contrast, DESI-MS is an ambient
technique that requires virtually no sample preparation, can be
performed on glass slides compatible with confocal Raman
spectroscopy thereby enabling true correlative analysis, and is
particularly suited to study lipids.26 This makes it an optimal
technique for studying the molecular composition of myelin.
Raman spectroscopic imaging (for structural information) and
DESI-MS imaging (for speciﬁc compositional proﬁling) can
provide two highly complementary techniques for lipid
characterization of brain tissue.
In this study, we developed a new correlated heterospectral
lipidomics (HSL) imaging strategy for molecular character-
ization and quantiﬁcation of remyelination based on correlative
Raman spectroscopy and DESI-MS analysis, validated with
immunolabeling for speciﬁc myelin proteins. We developed a
comprehensive computational library for pixelwise coregistra-
tion of Raman, DESI-MS hyperspectral data sets and
immunoﬂuorescence images. We harnessed the wealth of
Raman and DESI-MS hyperspectral data to generate a
heterospectral map for correlation of the biomolecular structure
and composition of tissue ex vivo. Multivariate regression
analysis enabled Raman-based assessment of highly speciﬁc
lipid subtypes in complex tissue for the ﬁrst time. We applied
the HSL approach to the characterization of remyelination in a
mouse model of focal demyelination as well as postmortem brain
samples with multiple sclerosis. Here we show for the ﬁrst time
diﬀerences in lipid composition not only between demyelinated
and normal brain tissue but, more importantly, between
remyelinated tissue and normal myelinated tissue.
■ RESULTS
Heterospectral Lipidomics (HSL) Workﬂow. Our
computational analysis framework takes full advantage of
Figure 1. Heterospectral lipidomics for analysis of myelination. Heterospectral lipidomics (HSL) workﬂow for studying myelin in animal models and
human tissue.
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Raman-based molecular structural information with subsequent
lipid composition information provided by DESI-MS imaging
(Figure 1). The data preprocessing, coregistration, and
multivariate analysis of the hyperspectral Raman and DESI-
MS images were combined into a comprehensive computa-
tional library in the Matlab environment (see Materials and
Methods). This allows us to generate a heterospectral map for
characterizing the lipidomics of brain tissue based on the
complementary structural and compositional information. The
heterospectral map can directly be used for spectral
interpretation including band assignment of overlapping
Raman peaks. Further, to enable Raman-based molecular
assessment of speciﬁc lipid species in the complex tissue we
demonstrate here the multivariate regression of the Raman
spectra (vibrational information) against the mass spectra
(molecular weight distribution information) using partial least-
squares (PLS) analysis.
We have also analyzed the two modalities independently
using multivariate statistical analysis. For quantitive myelin
analysis of the Raman data set, we deconvolved the tissue
Raman spectrum into myelin lipids and nonmyelinated tissue
using multivariate curve resolution (MCR).27,28 We used the
ratio of myelinated and nonmyelinated tissue from the MCR to
generate a Raman myelination index (RMI) representing the
relative amount of myelin in each sample. To conﬁrm the
ﬁdelity of the RMI-based myelin quantiﬁcation we used
immunoﬂuorescence for identifying myelin proteins, as a
well-established reference technique (Figure 1). For classi-
ﬁcation of the Raman spectra and DESI mass spectra we
employed the established PLS discriminant analysis (PLS-DA)
and maximum margin criterion linear discriminant analysis
(MMC-LDA), respectively.29
Heterospectral Raman Spectroscopy, DESI-MS, and
Immunoﬂuorescence Imaging of Brain Tissue Samples.
We ﬁrst acquired a high-resolution Raman spectroscopic image
(∼9500 × 6100 μm, spatial resolution of ∼10 μm) of a normal
coronal brain section (Figure 2A) containing over 930 million
data points (each pixel contains 1600 data points). Each Raman
Figure 2. Raman spectroscopy, desorption electrospray ionization mass spectrometry, and immunoﬂuorescence imaging of a mouse brain. (A)
Images of a coronal mouse brain section showing brightﬁeld image and Raman spectroscopy images associated with bands of lipids centered at 2850
cm−1, proteins at 2940 cm−1, and DNA at 3000 cm−1. Each spectrum in this image was baseline corrected with a linear polynomial and normalized in
the range 2780−3050 cm−1. Scale bar: 1 mm. (B) The Raman overlay of lipids, proteins, and DNA. Scale bar: 1 mm. (C) Representative staining for
myelin bound protein (MBP), Tuj1 (class III beta-tubulin), and 4′,6-diamidino-2-phenylindole (DAPI). Scale bar: 1 mm. (D) High resolution
microscopic Raman images of a region of interest in the mouse brain (200 × 200 μm) showing Raman spectroscopy peaks associated with lipids
(2885 cm−1), proteins (2940 cm−1), and DNA (3000 cm−1). Scale bar: 40 μm. (E) k-means clustering (n = 2 clusters) showing distinct signatures of
the brain tissue. (F) Representative mean Raman spectra associated with the two k-means clusters. (G) DESI-MS imaging of the major myelin
showing separation between gray and white matter based on m/z 848.63 and m/z 844.52 respectively, putatively assigned to Cer(d18:1/24:1) and
PC(38:6). (H) Representative mean DESI-MS spectra of gray and white matter (respectively in green and red).
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spectrum was collected with an acquisition time of 0.4 s.
Imaging the distinct lipid markers centered at 2850 cm−1
(symmetric CH2 stretching of lipids), protein content 2940
cm−1 (CH2 stretchings), and DNA at 3000 cm
−1 enabled
visualization of central nervous system (CNS) structural
features (Figure 2A,B,D). Major myelinated structures
including the corpus callosum and striatal ﬁber bundles could
clearly be demarcated from a background of axonal lipids.
Representative mean Raman spectra (identiﬁed using k-means
clustering, n = 2 clusters) are shown in Figure 2E,F with
noticeable Raman peaks listed in Supplementary Table S1. We
also constructed a spectral library of some of the major proteins
and lipids associated with myelin and CNS by collecting Raman
spectra of each puriﬁed lipid or recombinant protein, from
commercially available sources (Supplementary Figure S1).
Analysis of the single myelinated tissue component spectra
conﬁrms that the molecules largely contributing to myelinated
tissue spectra are lipids, including cerebroside, cholesterols,
sphingomyelin, phosphatidylcholine, and, to a much lesser
degree, proteins (Figure 2F).
We then conﬁrmed the molecular speciﬁcity of Raman
spectroscopy by correlative immunoﬂuorescence for MBP
(myelin basic protein), TUJ1 (beta3 tubulin), and DAPI
(nuclei) (Figure 2C). This shows that Raman spectroscopic
imaging provides highly detailed information about diﬀerent
biomolecular features in the tissue, down to the cellular level
(Figure 2D), similarly to conventional immunolabeling
techniques.
Since the immunostaining is inherently destructive, in a
sequential brain section we performed DESI-MS (spatial
resolution of ∼50 μm) and imaged the major myelin markers
based on m/z 848.63 and gray matter, based on m/z 844.52,
which were putatively assigned to Cer(d18:1/24:1) and
PC(38:6) respectively (Figure 2G). Representative mass
spectra of white and gray matter are shown in Figure 2H.
These results show it is possible to image lipids in myelin using
both Raman spectroscopic structural information and DESI-MS
for speciﬁc compositional proﬁling.
We ﬁnally showed that Raman spectroscopy and DESI-MS
can be performed sequentially on the same tissue sample. We
Figure 3. Pixelwise heterospectral Raman and DESI-MS. Heterospectral correlation maps between Raman and DESI-MS hyperspectral images
(negative mode). (A) DESI ion image showing the location of the ﬁducial markers with corresponding locations in panel B marked for the Raman
ion image. (C) The transformed DESI image with a region of interest showing the pixels used for correlative analysis of DESI and Raman data. (D)
Threshold of heterospectral correlation set at 0.2. (E) Threshold of correlation coeﬃcient set at 0.7. In both D and E the correlations with p > 0.05
were discounted. (F) PLS regression vector showing that the model is sensitive to the lipid speciﬁc peaks m/z 844.52. (G) PLS regression showing a
predictive model with an adjusted R-square of 0.825.
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performed direct HSL analysis by pixelwise coregistering the
Raman and DESI-MS hyperspectral image using our developed
computational framework (Figure 3A−C), focusing on the
corpus callosum (Supplementary Figure 2 shows the
anatomical structure within the context of the brain section).
This allowed us to generate a heterospectral DESI-MS and
Raman correlation map that enables the assignment of
structural features detected by vibrational spectroscopy to
individual molecular species detected by mass spectrometry
(Figure 3D,E). Generally, the data showed a high degree of
correlation between Raman vibrational peaks associated with
the myriad of diﬀerent lipids. For instance, we found the
strongest positive correlation for the CH2 deformation
vibrations near 1440 cm−1 and ν(CC) at 1650 cm−1 and
mass peaks at m/z 844.52 suggestive of PC(38:6) lipids
(correlation coeﬃcient >0.79 for 1440 cm−1, and correlation
coeﬃcient >0.56 for 1650 cm−1). This technique also revealed
the subtle and apparently buried Raman peaks that cannot be
assessed using Raman spectroscopy alone (e.g., weak C−C
stretching bands of lipids in the range 1050−1200 cm−1).
Conversely, as expected, the most common protein Raman
peaks (e.g., the amide III at 1245 cm−1 and highly speciﬁc
phenylalanine Raman peak near 1004 cm−1) correlated poorly
with any of the masses. Interestingly, we also observed negative
correlations, in particular for the cytochrome resonance Raman
peaks of mitochondria (e.g., near 748 and 1585 cm−1). This is
likely because white matter contains an abundance of lipids and
therefore relatively fewer mitochondria per volume compared
to gray matter. Hence, once a single heterospectral map has
been developed for a speciﬁc tissue type, this can improve
spectral interpretation including band assignment of over-
lapping Raman peaks and allows us to better understand the
compositional origin of overlapping Raman peaks in biological
complex samples and vice versa for DESI-MS imaging. Since
excellent correlation could be achieved, we then performed a
PLS multivariate regression of the Raman spectra against the
mass spectra (see Materials and Methods). As an example we
regressed the Raman spectrum against the m/z 844.52
PC(38:6). The regression vector showed highly speciﬁc lipid
peaks indicating speciﬁcity to phosphatidylcholine (Figure 3F).
The regression analysis showed that a highly linear relationship
could be established (adjusted R2 = 0.825) (Figure 3G).
Assumingin a ﬁrst approximationlinearity of the mass
spectrum with concentration, this Raman-based model can
serve as a predictor of speciﬁc lipid species in complex tissue.
These results represent a novel demonstration of lipidomic
proﬁling using complementary spectral modalities based on
both structural and biomolecular information.
Heterospectral Lipidomics in a Mouse Model. We ﬁrst
applied our HSL characterization to tissue from a mouse model
of demyelination as a proof of principle. We assembled
correlative images that incorporate speciﬁc immunolabeling for
MBP with the Raman k-mean clustering images (n = 2 clusters)
for the lipid component using ImageJ and found that the lipid-
rich component identiﬁed correlated well with the MBP+
myelinated areas in the tissue (Supplementary Figure S2).
We then used a mouse model of focal demyelination based
on stereotactic injection of lysophosphatidylcholine (LPC) into
the mouse corpus callosum.11 We acquired high resolution
Raman spectroscopic images (n = 15) of the corpus callosum in
ﬁxed coronal brain sections. We analyzed sections taken from
days 14, 21, and 28 after LPC injection in order to cover the
whole process from demyelination to complete remyelination
(day 28 post injection). We used two controls: noninjected
mice (control) and mice injected with saline only at day 14 post
injection (i.e., with no demyelination). We then calculated the
RMI (see Materials and Methods) at diﬀerent time points post
LPC injection by deconvolving the myelinated tissue spectrum
using MCR (Figure 4A). Figure 4A displays two pure MCR
basis spectra essentially representing myelin lipids and
Figure 4. Quantiﬁcation of remyelination in a mouse model using RMI. (A) MCR deconvolved pure components representing demyelinated tissue
and myelinated tissue with marked signatures for lipids. The ratio of myelinated to demyelinated tissue was used to form the RMI (most relevant
peaks highlighted). (B) Images of RMI, correlative immunostaining for MBP, and 4′,6-diamidino-2-phenylindole (DAPI) staining for control, 14 and
28 days post LPC injection. Scale bar: 500 μm. (C) Mean RMI, MBP, and DAPI fold change ± 1 standard error compared to contralateral
hemisphere for 14, 21, and 28 days post injection. Also shown are control (nontreated) and saline injected (day 14). * indicates p < 0.05 (one-way
ANOVA: for RMI fold change p = 0.006, Newman−Keuls post-test LPC day 14 vs day 28/control/saline p < 0.05; for MBP fold change p = 0.002,
Newman−Keuls post-test LPC day 14 vs day 28/control p < 0.05).
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demyelinated axons accounting for 90.68% (component 1,
61.55%, component 2, 29.13%, respectively) of the spectral
variance. The omitted residual (7.39%) in the model was
associated with artifacts from tissue preparation and cover glass
background signal. Since MCR is based on spectral variance
and because the amount of myelin lipids is the source of
signiﬁcant spectral variability in the image, MCR is able to
estimate a spectrum of myelin lipids (Figure 4A). This is also
evident by comparing the myelin signature with the pure lipids
(Supplementary Figure S1) as well as the strong correlations in
the heterospectral map (Figure 3D,E).
To validate the RMI for myelin quantiﬁcation, we performed
correlative immunohistochemistry for MBP and DAPI on the
same tissues and used the immunoﬂuorescence image to deﬁne
injected and noninjected regions of interest (ROI) on each
section (Supplementary Figure S3). These ROIs were then
used to generate binary masks and extract the RMI. For this
myelin quantiﬁcation, the signal density from either MBP
immunostaining or RMI images was calculated as a ratio of the
signal density on the injected side of the corpus callosum
compared to the noninjected side. The densitometry ratio of
injected vs noninjected side for each sample was then
normalized to the values obtained with control sections from
untreated mice. We have summarized the average RMI ± 1
standard error (SE) at diﬀerent time points (Figure 4C left
panel). The results of this quantiﬁcation showed a 52%
reduction in myelin (0.50 fold decrease compared to 0.95 of
control, ±0.14 fold change) at 14 days after injection compared
to controls (p < 0.05). During remyelination, the RMI
increased to 62% compared to the control untreated mice
(0.61 fold decrease compared to 0.95 of control, ±0.12 fold
change) at day 21 after lesion induction, and after 28 days the
RMI progressively reverted back to control levels (0.96 fold
decrease compared to 0.95 of control, ±0.03 fold change).
These values correlated well with the MBP densitometric
analysis performed on the correlative immunoﬂuorescence
images (Figure 4C central panel). The signiﬁcant increase in
DAPI+ cells observed at day 14 after LPC injection (1.4 fold
increase ± 0.13, p < 0.05) compared to control corresponds to
an accumulation of microglia/macrophages in the lesion, which
we identiﬁed by correlative immunoﬂuorescence for the
microglial marker IBA1 in a subset of sections already analyzed
by Raman spectroscopy (Supplementary Figure S4). Along
with the increased microglia/macrophage inﬁltration into
demyelinated lesions, Raman spectroscopy also revealed the
presence of cholesterol esters (through the presence of the
ester vibrational mode at 1745 cm−1), generally around the
lesion site, suggestive of end products of myelin degradation,
which is performed and then cleared by these cells.
We next assessed whether Raman analysis could identify
speciﬁc biomolecular structural diﬀerences for diﬀerent levels of
myelination. We ﬁrst calculated the mean Raman spectra ± 1
SD using the ROIs deﬁned above as a guide (Figure 5A,
Supplementary Figure S5A), and then we calculated the mean
diﬀerence spectra for each time point to uncover subtle
molecular diﬀerences between samples (Figure 5B, Supple-
mentary Figure S5B). Spectral analysis showed that demyeli-
nated lesions are associated with a distinct Raman spectroscopic
proﬁle, with reduction and/or spectral shifting in the peaks
1078, 1302, 1445, and 1650 cm−1. Interestingly, there were
spectral diﬀerences between normally myelinated and remyeli-
nated tissue (day 28 post LPC injection). To investigate this
Figure 5. Heterospectral lipidomics of remyelinated lesions in a focal demyelination mouse model. (A, B) Mean Raman spectra ± 1 standard
deviation (SD) of normal myelinated tissues (noninjected side) and remyelinated tissue (injected side, day 28 post toxin injection). (B) Mean
diﬀerence spectra ± 1 SD (injected side, contralateral) showing the remyelination process at the structural level. (C) PLS-DA posterior probability
image based on Raman spectroscopy of remyelinated sample discriminating control side (green) and injected side (red). Yellow represents nearly
equal probability. (D, G) Mean DESI-MS mass spectra of normal myelinated tissues (noninjected side) and remyelinated tissue (injected side, day
28 post toxin injection) for negative and positive ion mode, respectively. (E, H) Mean diﬀerence spectra between remyelinated (day 28 post toxin
injection) and control noninjected side for negative and positive ion mode, respectively. (F, I) MMC-LDA posterior probability based on DESI-MS
negative ion mode and positive mode respectively belonging to control side (green) or injected side (red). Yellow represents nearly equal probability
(images were rotated for presentation in this ﬁgure; originals are shown in Supplementary Figure S6D,E). Scale bar 250 μm.
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further, we performed PLS-DA on a day 28 tissue
(remyelinated) compared to contralateral control and gray
matter tissue. The 8 component PLS-DA accounted for 61.95%
of the total variance where the ﬁrst four latent variables (LVs)
(LV1, 49.59%; LV2, 6.16%; LV3, 1.12%; and LV4, 1.77%)
corresponded mostly to lipid peaks (e.g., CH2 deformations at
1440 and CC stretchings at 1650 cm−1) (Supplementary
Figure S6A and Figure 3D). Based on this analysis, we then
Table 1. DESI-MS Peak Annotation for Mouse Remyelinated Tissuea
m/z value identiﬁcation ion type accurate mass fold change (remyelinated vs control)
Positive Ion Mode
770.49 PC (32:1) [M + K]+ 770.5097 0.7367
848.53 PC (38:4) [M + K]+ 848.5566 0.8416
826.56 PC (36:1) [M + K]+ 826.5723 0.8531
810.58 PC (36:1) [M + Na]+ 810.5983 0.8533
824.53 PC (36:2) [M + K]+ 824.5566 0.8893
772.51 PC (32:0) [M + K]+ 772.5253 1.1367
806.55 PC (32:3) [M + Na]+ 806.567 1.4514
806.55 PC(38:3) or PC(40:6) [M + Na]+ or [M + H] 834.5983 or 834.6007 1.4527
806.55 PE (40:6) [M + Na]+ 814.5357 1.4718
872.54 PC (40:6) [M + K]+ 872.5566 1.5848
844.51 PC (38:6) [M + K]+ 844.5253 1.6879
Negative Ion Mode
700.51 fragment of PE(34:1) PE(34:1) − NH2 − H 700.5049 0.8488
700.51 PE(20:4/16:0) [M − H]− 766.5392 1.1528
762.49 PE(16:0/22:6) [M − H]− 762.5079 1.3086
774.52 PE(16:0/22:6) [PE(40:6) − NH2 − H]− 774.5205 1.3314
790.53 PE(18:0/22:6) [M − H]− 790.5392 1.4966
aThe most signiﬁcant mass spectrometry peaks in negative and positive ion mode identiﬁed using maximum margin criterion linear discriminant
analysis (MMC-LDA) for discriminating between remyelinated and normal myelinated areas of the corpus callosum in the mouse model of toxin
induced focal demyelination, conﬁrmed by MSMS.
Figure 6. Heterospectral lipidomics of human multiple sclerosis brain. (A) Mean Raman spectra ± 1 standard deviation (SD) of normal appearing
white matter (NAWM) and remyelinated lesions. (B) Mean diﬀerence spectra ± 1 SD (NAWM − remyelinated lesion) showing the remyelination
process at the structural level. (C) PLS-DA posterior probability image based on Raman spectroscopy of remyelinated lesions highlighting NAWM
(green) and remyelinated tissue (red). (D, G) Mean DESI-MS mass spectra of NAWM and remyelinated lesions for negative and positive ion mode,
respectively. (E, H) Mean diﬀerence spectra between NAWM and remyelinated lesions for negative and positive ion mode respectively. (F, I) MMC-
LDA posterior probability based on DESI-MS negative ion mode and positive mode respectively of belonging to NAWM (green) or remyelinated
lesion (red). Yellow represents nearly equal probability. Scale bar 750 μm.
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constructed an image of the corpus callosum that shows the
probability of each pixel belonging to either the injected side
(red) or noninjected side (green) (Figure 5C). These results
show that newly formed myelin in remyelination can to some
extent be distinguished from normal myelin using Raman
imaging. The data presented thus far shows that Raman based
characterization can detect subtle diﬀerences in the molecular
structure of remyelinated and normal tissue.
The Raman myelination analysis was initially performed on
ﬁxed brain tissue. Since DESI-MS must be performed on fresh
tissue, in addition, this allowed us to compare ﬁxed and
nonﬁxed brain to investigate potential diﬀerences introduced by
the ﬁxation process to the Raman proﬁling of brain tissue. The
ﬁxation process induces subtle molecular changes in the corpus
callosum mostly around 1450 cm−1 associated with CH2
deformations (Supplementary Figure S7), most likely due to
conformational changes in proteins occurring during form-
aldehyde ﬁxation. All subsequent Raman myelination analysis
was performed on unﬁxed tissue, which was then immediately
imaged with DESI-MS.
Following Raman spectroscopy, DESI-MS images were
acquired from fresh mouse brain samples (remyelinated lesion
(injected side at day 28) and contralateral normal side
(noninjected side)). We calculated the average DESI mass
spectra in the negative and positive ion modes (Figure 5D,G)
as well as the mean diﬀerence spectra to highlight dissimilarities
between the DESI mass spectra of the diﬀerent samples (Figure
5E,H). To identify those masses that best diﬀerentiate
remyelinated from control tissue, we performed MMC-
LDA.29 We calculated the MMC-LDA loading vectors for the
negative and positive modes (Supplementary Figure S6B,C).
We then produced images that show the posterior probability
of belonging to the injected (red) or noninjected side (green).
This analysis essentially conﬁrmed the Raman spectral
characterization and showed highly speciﬁc molecular changes
in the remyelinated lesion (injected side) compared to the
contralateral normal side (noninjected side), in particular for
the positive ion mode (Figure 5F,I). The most signiﬁcant peaks
discriminating remyelinated and normal myelinated areas of the
corpus callosum were then conﬁrmed by tandem mass
spectrometry (see Materials and Methods) and are reported
in Table 1. The main diﬀerences between normal myelin and
remyelinated tissue are generally due to changes in the
composition of phosphatidylcholines (PCs) and phosphatidy-
lethanolamines (PEs) within the analyzed areas. Hence, both
the Raman and DESI-MS suggest that the lipid composition of
remyelinated regions diﬀers from that of original myelin. The
results obtained from the mouse model serve as a proof of
principle to show that HSL imaging can eﬀectively investigate
the lipidomic proﬁle of remyelinated lesions, as well as
providing the ﬁrst direct indication that newly formed myelin
after demyelination presents a distinct molecular signature and
a relative lipid composition diﬀerence compared to normal
myelin.
Application of Heterospectral Lipidomics to Multiple
Sclerosis Patient Brain Samples. We ﬁnally applied our
HSL approach to multiple sclerosis lesions from human
postmortem brain samples for label-free lesion classiﬁcation
and lipidomic analysis. We obtained normal control brain
samples (n = 4) and multiple sclerosis brain samples containing
chronic active demyelinated lesions (n = 6), chronic inactive
demyelinated lesions (n = 8), and remyelinated lesions (n = 4)
from 8 multiple sclerosis patients. A total of 83,116 Raman
spectra were measured from normal control tissue (n = 29,316
spectra), combined chronic active and inactive multiple
sclerosis lesions (n = 14,354 spectra), and remyelinated lesions
(n = 39,446 spectra) (Figure 6A and Supplementary Figure
S8A). We calculated the diﬀerence spectra ± 1 SD to uncover
the molecular diﬀerences associated with each tissue type
(Figure 6B and Supplementary Figure S8B).
Although the pixelwise coregistrated HSL map we developed
(Figure 3) was based on mouse tissue, it also informed our
interpretation of the Raman spectra from human tissues. The
multiple sclerosis remyelinated lesions showed less complete
remyelination compared to the remyelination in the mouse
model, as indicated by the lower intensity of lipid peaks at
1302, 1445, and 1650 cm−1. There were also more pronounced
peaks of mitochondria such as 1585 cm−1 associated with
cellular inﬁltration of the lesion (Figure 6B). As in the mouse
model, the Raman based analysis successfully identiﬁed speciﬁc
signatures not only for demyelinated lesions but also for
remyelinated lesions.
To further study these compositional diﬀerences, we
performed correlative DESI-MS by comparing remyelinated
lesions from 8 multiple sclerosis patient brains (identiﬁed by
histopathological classiﬁcation) with normal appearing white
matter tissue from the same patient aiming to obtain the
speciﬁc lipid proﬁle associated with remyelinated lesions in
patients (Figure 6D−I). We performed MMC-LDA to identify
the most discriminative peaks that accounted for the diﬀerences
observed between remyelinated and normal appearing white
matter (Supplementary Figure S6C). The identiﬁed lipids were
then conﬁrmed by tandem mass spectrometry and are reported
in Table 2. As observed in the mouse tissue analysis, the
remyelinated areas diﬀer mainly in the composition of the PC
and PE lipid populations. These results indicate that HSL
imaging can be eﬀectively employed for lipidomic proﬁling of
postmortem multiple sclerosis patient lesions, and suggest that
the myelin produced during remyelination in multiple sclerosis
has an altered lipid proﬁle, when compared to nearby normal
appearing white matter.
■ DISCUSSION
In this study, we developed a new heterospectral lipidomics
(HSL) imaging method, for the classiﬁcation and molecular
characterization of myelination in both an animal model and
human multiple sclerosis brain samples, and used it to directly
observe for the ﬁrst time that newly formed myelin is
compositionally diﬀerent from normal myelinated tissue. To
harness the large amount of data generated, we developed a
comprehensive computational library for correlative hetero-
spectral imaging. The combined use of Raman spectroscopy
and DESI-MS within the HSL workﬂow oﬀers a simple and yet
highly eﬀective approach to proﬁle the lipidomics of de- and
remyelinated tissue at both the structural and compositional
levels. In contrast to other techniques such as MALDI, our
DESI-MS has the major advantage that it can be performed
with no initial preparation on the same sample as for Raman
spectroscopy thereby enabling true correlative analysis. Here
we developed the ﬁrst pixelwise coregistration approach for
heterospectral Raman and DESI-MS imaging analysis. This
allowed us to generate a correlation map that describes how the
distinct vibrational molecular structural features correlate with
compositional analysis. Further, we also showed for the ﬁrst
time that multivariate regression analysis between Raman
spectra and mass spectra has the potential to enable Raman-
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based characterization of highly speciﬁc lipid species in complex
tissue.
Our results indicate that Raman spectroscopy can discrim-
inate between normal, demyelinated, and remyelinated areas in
our mouse model and in human multiple sclerosis tissue,
avoiding classical destructive and time-consuming analyses. In
addition, we showed that Raman spectral analysis could identify
structural diﬀerences not only between demyelinated and
control tissue (comparable to that obtained with MBP
staining), but importantly between control and remyelinated
tissue, oﬀering for the ﬁrst time a speciﬁc comprehensive and
distinct molecular signature for remyelinated tissue, with most
of the diﬀerences in the lipid components. This concurs with
previous knowledge that remyelinated and myelinated intern-
odes have very similar protein components, but remyelinated
myelin sheaths are thinner (due to less myelin wrapping).30
The HSL correlation map enabled us to gain deeper insight
into the biomolecular origin of the highly overlapping Raman
peaks. Moreover, Raman spectroscopy enables a detailed
structural molecular characterization of the tissue, as it not
only can quantify the lipid component but also provides
additional information on the underlying disease processes
(such as immune inﬁltration, increased mitochondria, etc.)
without requiring multiple immunostainings of serial histo-
logical sections.
Correlative DESI-MS analysis showed that some lipids can
be over-represented in remyelinated myelin as well as under-
represented, suggesting that remyelination can diﬀer from
normal myelin in more than simply a reduced amount of lipid
secondary to a thinner sheath. PCs and PEs are two of the
major constituents of mammalian cell membranes including
those of myelin, and they account for most of the diﬀerences
between remyelinated and normal myelin in both the mouse
and human multiple sclerosis brains. In the focal demyelination
mouse model, we found a trend toward decrease in some
polyunsaturated PEs and PCs in remyelinated tissue, and a
corresponding increase in PCs with higher saturation levels,
which could correlate with the thinner myelin sheaths. In
human remyelinated multiple sclerosis lesions we also observed
a similar shift in several PC and PE species, but the exact
changes are more complex to interpret. However, it is
interesting to observe that both mouse and human remyeli-
nated tissue showed an increase in PC(32:0), a phosphati-
dylcholine normally present in greater abundance within gray
matter.31 The reasons for some discrepancy between the
remyelinated lesions in the mouse and human data sets may be
due to intrinsic diﬀerences in lipid content in myelin between
species, to interindividual/anatomical variations typical of
patient samples. In fact, while in the mouse samples we had
precise control over the anatomical area of the lesion (i.e.,
corpus callosum), the multiple sclerosis lesions came from
diﬀerent anatomical regions of the brain, and are certainly more
heterogeneous than the murine samples along the remyelina-
tion timeline. However, given the scarcity of lipidomic data on
myelin composition in health and pathology in both mouse and
human, partially due to a previous lack of accessible and reliable
techniques to perform these studies, we believe that these
results oﬀer an important, if preliminary, step toward a better
understanding of remyelination, as they directly highlight
previously unrecognized diﬀerences between myelin formed
during endogenous regeneration and normal myelinated tissue.
Using these techniques, and a bigger data set of patient
samples, one will be able to address lipid variations in
remyelinated multiple sclerosis lesions within a patient
(removing genetic background variation) and between
remyelinated lesions in similar locations between patients
(reducing anatomical variation). Furthermore, as we know that
myelin changes with age both at the ultrastructural level32,33
and in terms of its lipid components,34 this raises questions
such as whether the lipid content of remyelinated myelin is
more similar to young or old myelin, or diﬀerent from both,
and whether this changes in a similar way over time. Now that
we have proof of principle that this strategy is suitable, we may
answer these questions, both in animal models and by
examining human multiple sclerosis samples of diﬀerent ages,
compared to controls of diﬀerent ages. It is also important to
determine whether the quality of remyelinated myelin is
equivalent to normal myelin, whether it matures/ages at a
diﬀerent rate, and whether it can change in response to need,
for example as required in activity-dependent myelination.35
This has pertinence for the development of pro-remyelinating
drugs as therapies in multiple sclerosis.
The HSL strategy developed here represents a powerful tool
to classify, quantify, and analyze lipids in myelin, increasing
information for selecting the most promising pro-remyelination
therapeutic strategies. Understanding lipid structural and
compositional diﬀerences between myelination and remyelina-
tion may allow us to identify remyelinated areas more
eﬃciently. The HSL imaging workﬂow presented here will
allow one to investigate speciﬁc questions such as whether
these lipid diﬀerences alter the function of myelin, in terms of
the eﬃciency of saltatory conduction and the metabolic support
Table 2. DESI-MS Peak Annotation for Human
Remyelinated Lesionsa
m/z value identiﬁcation ion type
accurate
mass
fold change
(remyelinated
vs control)
Positive Ion Mode
848.53 PC (38:4) [M + K]+ 848.5566 0.449
834.57 PC(38:3) [M + Na]+ 834.5983 0.4628
814.51 PE (40:6) [M + Na]+ 814.5357 0.4689
810.58 PC (36:1) [M + Na]+ 814.5357 0.5674
826.56 PC (36:1) [M + K]+ 826.5723 0.6284
824.53 PC (36:2) [M + K]+ 824.5566 0.7083
806.49 PE (38:4) [M + K]+ 806.5096 1.0512
872.54 PC (40:6) [M + K]+ 872.5566 1.2509
844.51 PC (38:6) [M + K]+ 844.5253 1.5723
770.49 PC (32:1) [M + K]+ 770.5097 1.6884
772.51 PC (32:0) [M + K]+ 772.5253 2.2756
Negative Ion Mode
762.49 PE(16:0/22:6) [M − H]− 762.5079 0.7603
700.51 PE(16:0/18:1) [PE(34:1) −
NH2 −
H]−
700.5049 0.8252
790.53 PE(18:0/22:6) [M − H]− 790.5392 1.9916
774.52 fragment of
PE(40:6)
[PE(40:6) −
NH2 −
H]−
774.5205 2.2611
774.52 fragment of
PE(18:0/22:6)]
[PE(40:6) −
C2H4NH2
− H]−
746.4892 2.4167
766.53 PE(20:4/16:0) [M − H]− 762.5392 3.0029
aThe most signiﬁcant mass spectrometry peaks in negative and
positive ion mode identiﬁed using maximum margin criterion linear
discriminant analysis (MMC-LDA) for discriminating between
remyelinated and normal myelinated tissue in human brain samples,
conﬁrmed by MSMS.
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to the underlying axon. In addition, future pragmatic studies
could aim to apply simultaneous Raman and mass spectrometry
for living tissue assessment as well as clinical applications
toward lipidomic diagnostics. Both Raman spectroscopy and
some mass spectroscopy approaches are in principle compatible
with clinical applications.36 Furthermore, the multivariate
regression approach that we presented in this work can ﬁnd
widespread applications to uncover the plurality of molecular
species in complex biological tissue.
In summary, we have developed a heterospectral lipidomics
(HSL) methodology to quantify and characterize remyelination
in a mouse model of induced focal demyelination and in human
multiple sclerosis lesions. We demonstrated the ﬁrst pixelwise
coregistered heterospectral application of Raman spectroscopy
and DESI-MS imaging. This analysis provides the ﬁrst
indication that newly formed myelin after demyelination has
a diﬀerent lipid composition compared to normal myelin.
Hence, this HSL methodology may substantially improve the
current understanding of remyelination in multiple sclerosis
and may provide a new strategy to assess remyelination
treatments in multiple sclerosis research. Furthermore, the HSL
approach can be tailored to a broad range of tissues, providing
crucial insights into lipid structure and composition in
biomedical sciences.
■ MATERIALS AND METHODS
Animals. Animal work was carried out in accordance with
the University of Edinburgh regulations under Home Oﬃce
rules (PPL 60/4524), with local ethics committee consent.
Animals were randomly allocated a treatment group.
Lesion Induction and Surgery. Myelin toxin lysophos-
phatidylcholine (LPC) was stereotactically injected into mouse
corpus callosum to cause focal demyelination while leaving
axons intact. The time course of demyelination and
remyelination ensues in a stereotyped way, with a fully
developed demyelinated lesion at 3 days post injection followed
by spontaneous remyelination to completion in 4 weeks.37
Using anesthetized 12−14-week-old C57Bl/6 male mice (n = 3
per time point), 2 μL of 1% (w/v) LPC (Sigma-Aldrich, UK)
was injected through a hole drilled in the skull at stereotactic
coordinates 1.2 mm posterior, 0.5 mm lateral, 1.4 mm deep to
the bregma over 4 min using a 30 gauge needle attached to a
Hamilton syringe, driven by a Nano pump (KD Scientiﬁc Inc.,
Holliston, MA), which was left in situ for 4 min to reduce
backﬂow. A surgical sham control was also prepared by
injecting phosphate-buﬀered saline (0.9% sodium chloride
solution) in the same way. Mice were sacriﬁced at predeﬁned
time points (14, 21, and 28 days) post lesion induction.
Mice Tissue Section Preparation. Mice were terminally
anesthetized and perfused transcardially either with 4% (w/v)
paraformaldehyde (PFA) solution (for Raman analysis) or with
phosphate-buﬀered saline (0.9% (w/v) sodium chloride
solution) (for DESI analysis) at 14, 21, or 28 days post
injection. For Raman analysis, brains were dissected and
postﬁxed in 4% (w/v) PFA for a further 24 h, before immersion
in increasing concentrations of sucrose solutions, and frozen in
OCT embedding matrix. For DESI analysis, brains were ﬂash
frozen without ﬁxation. Using a cryostat (Leica Inc. GmbH), 10
μm coronal sections were cut onto magnesium ﬂuoride slides
(Global Optics Ltd., UK) (Raman analysis) or Superfrost Plus
(VWR International LLC Inc., Radnor, PA) adhesive glass
slides (DESI analysis) and stored at −20 °C until use.
Human Brain Tissue Samples. Postmortem unﬁxed frozen
tissue was obtained from the UK Multiple Sclerosis Tissue
Bank via a UK prospective donor scheme with full ethical
approval (MREC/02/2/39). Two independent researchers
characterized the lesion types as chronic active, chronic
inactive, or remyelinated using Luxol fast blue to detect myelin
and Oil red O staining to detect macrophages/microglia.11
Chronic active lesions have a demyelinated core with few
inﬂammatory cells, but a ring of lipid-laden macrophages/
microglia at their edge. Chronic inactive lesions have a sharp
edge on LFB and few inﬂammatory cells throughout.
Remyelinated lesions are ﬁlled with thin (pale-staining) myelin,
with very few inﬂammatory cells remaining. We obtained
normal control brain samples with no neurological disease (n =
4) and multiple sclerosis brain samples containing chronic
active demyelinated lesions (n = 6), chronic inactive
demyelinated lesions (n = 8), and remyelinated lesions (n =
4) from 8 diﬀerent multiple sclerosis patients.
Reference Biochemicals. We constructed a spectral library
of reference biochemicals representing the major proteins and
lipids in CNS including MBP (M2941, Sigma-Aldrich (UK)),
actin (C3653, Sigma-Aldrich (UK)), phosphatidylcholine
(P3556), glycerophosphatidylcholine (S4335) sphingomyelin
(860062, Avanti Polar Lipids Inc., Alabaster, AL), cholesterol
(C8667, Sigma-Aldrich (UK)), DOPC (C8667, Sigma-Aldrich
(UK)), galactocerebrosides (C4905, Sigma-Aldrich (UK)),
cerebroside sulfate (S1006, Sigma-Aldrich (UK)), and LPC
(L1381, Sigma-Aldrich (UK)). The Raman spectra of these
reference biochemicals were all measured in native state on a
magnesium ﬂuoride (MgF2) slide.
Raman Spectroscopy Imaging. The confocal Raman
microspectroscopy system used in this study consists of an
upright microscope (Alpha 3000, WITec, GmbH, Ulm)
equipped with a piezoelectric stage (UHTS 300, WITec,
GmbH, Ulm). A green laser (λex = 532 nm, WITec GmbH,
Ulm) with maximum output of 75 mW was ﬁber-coupled into
the microscope using a 10 μm low OH silica ﬁber. The
backscattered Raman signals were fed into a high-throughput
imaging spectrograph (UHTS 300, WITec GmbH, Ulm),
equipped with a thermoelectrically cooled (−60 °C), charge-
coupled device (CCD) camera (Newton, Andor Technology
Ltd., UK, Belfast) using a 100 μm low OH silica ﬁber. The
system acquires Raman spectra in the range from 0 to 3600
cm−1 with a spectral resolution of ∼13 cm−1.
For mice, Raman spectroscopy images (∼3000 × 1500 μm
(spatial resolution of ∼6 μm)) were measured by raster
scanning over contralateral regions of corpus callosum. Each
Raman spectrum was collected with an acquisition time of ∼1.0
s and a power on the sample of ∼13 mW using the 532 nm
laser excitation. No sample degradation due to heating was
noticed using this power density. We did observe ﬂuorescence
bleaching for brain tissue using the 532 nm laser.
For human samples, Raman images were measured by raster
scanning covering lesions and control tissue. We measured
tissue from n = 8 patients. For each tissue/lesion we measured
∼2500 spectra in quadratic ROIs that each were 150 × 150 to
180 × 180 μm in size. Each Raman spectrum was collected with
an acquisition time of ∼1.0 s and a power on the sample of ∼13
mW using the 532 nm laser excitation.
Raman Data Analysis. Before multivariate statistical
analysis, the Raman spectra were preprocessed. First, to remove
tissue autoﬂuorescence, a constrained second-order polynomial
was ﬁtted to the raw spectrum in the range 500−3600 cm−1,
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and this polynomial was then subtracted to yield the Raman
spectrum alone. This was performed in the Project Four
(WITec, Ulm, Germany). Each Raman spectrum was
normalized to its total intensity. For univariate analysis we
imaged the high wavenumber (due to higher signal intensity).
For multivariate analysis and discrimination of subtle diﬀerence
we analyzed the more speciﬁc ﬁngerprint range.
Regions within the sample were annotated as either “control”
or “lesion”. These annotated pixels were extracted and analyzed
using partial least-squares discriminant analysis (PLS-DA) and
internal 10-fold cross validation.
k-means clustering (n = 2 clusters) was calculated in Project
Four (WITec, Ulm, Germany) and used to coregister myelin
lipids and MBP staining.
The Raman myelination index (RMI) was calculated using
using non-negativity constrained MCR in the Matlab 2014b
programming environment (MathWorks). All hyperspectral
Raman images were combined into a single data set and
analyzed together. A model complexity of three components
essentially representing myelin, nonmyelinated tissue, and a
residual (glass interference) provided an optimum molecular
contrast of myelin in CNS tissue. The residuals were discarded
and the two MCR components (myelin lipids and non-
myelinated tissue) were divided to form the RMI as a measure
of the relative amount of myelin per axon area. All RMI values
were normalized to the control hemisphere.
Immunohistochemistry. For immunostaining, brain slices
were ﬁrst treated with ice cold ethanol for 10 min for
delipidation and then washed in PBS three times for 5 min,
before addition of blocking solution (10% (v/v) donkey serum
in TX-PBS 0.2% (v/v)). The primary antibodies (rat anti-MBP,
Serotec Cat. No. MCA409S used at 1:200; mouse anti Beta3
Tubulin, Sigma-Aldrich Cat. No. T5076 used at 1:1000; goat
anti-IBA1, Novus Cat. No. NB100-1028 used at 1:200) were
added in blocking solution to each slide and incubated
overnight at 4 °C. After the primary antibody incubation, the
slides were washed in PBS three times for 5 min, before
addition of the secondary antibody in blocking solution for 1.5
h. After the secondary incubation, the slides were incubated in a
1:5000 DAPI−PBS solution for 5 min before three ﬁnal washes
in TX-PBS 0.2% (v/v) before mounting. All antibodies were
validated for speciﬁcity and background performing secondary
only controls on additional mouse brain sections.
Raman and Immunoﬂuorescence Coregistration. To
enable correlative imaging, we then developed a comprehensive
Matlab library for correlative Raman spectroscopy processing
and immunoﬂuorescence imaging. This library enables us to
spatially overlay a database of Raman and immunoﬂuorescence
images and extract the average signature according to a used-
deﬁned ROI. Inverse trapezoidal ROIs of the left and right sides
of the corpus callosum stained for MBP were deﬁned in ImageJ
and used to create bounding masks for the treated and control
areas. The masked images were then linearly down sampled to
match the resolution of the Raman spectroscopic images.
Finally the masks were overlaid with the Raman spectroscopic
images for correlative imaging using ImageJ. Quantiﬁcation of
myelination in brain sections for both RMI and MBP images
was conducted by measuring the density of signal in the masked
areas (noninjected side vs injected side), which was then
divided by the area of the ROI. The measurements were then
used to create a ratio of signal density between treated and
untreated areas, which were then normalized on the values of
control samples and expressed as fold change for the
representation. Since for each condition we have 3 images,
we pooled the RMI of the 3 replicates using only the pixels
belonging to the same region, as inferred by the image
registration. The control normalization was achieved by
dividing all RMI values by the average value for the 3 control
pooled replicates. Statistical analysis on the obtained data was
performed using one-way ANOVA with Newman−Keuls post-
test.
DESI-MS Imaging. Fresh frozen tissue sections were
thawed at room temperature before being analyzed by DESI-
MS. DESI-MS imaging was performed on a Xevo G2-XS
quadrupole time-of-ﬂight mass spectrometer (Waters Corpo-
ration, Milford, MA) equipped with a 2D DESI stage obtained
from Prosolia Inc. (Indianapolis, IN), and a custom-built inlet
capillary heated to 490 °C. DESI parameters were optimized for
best spatial resolution on tissue and were as follows: spray
voltage, 4.5 kV; solvent, methanol/water, 95:5; ﬂow rate, 0.5
μL/min; nebulizing gas, nitrogen; gas pressure, 4 bar; sprayer
incidence angle, 75°; collection angle, 10°; sprayer-to-inlet
distance, 8 mm; sprayer-to-sample distance, 0.5 mm. Mass
spectrometric parameters were as follows: source temperature,
120 °C; source oﬀset, −80 V; 4 scans/s. Mouse brain samples
were imaged at a nominal pixel size of 25 μm; the full mouse
brain sample (Figure 2G) and human brain samples were
imaged at a nominal pixel size of 50 μm.
MSMS Fragmentation. To identify the signiﬁcant features,
MSMS fragmentation was performed using a LTQ Orbitrap
Discovery (Thermo Fischer Scientiﬁc Inc., Waltham, MA,
USA) linear ion trap equipped with a home-built computer
controlled 2D sampling stage and DESI-sprayer. The sprayer
voltage was set to 4.5 kV for both positive and negative
acquisition modes. A mixture of methanol/water (95%/5%)
was delivered with a ﬂow rate of 1.5 μL/min and nebulized with
a N2 gas pressure of 6 bar. Spectra were isolated from line scans
across a mouse brain section performed with a sample moving
speed of 50 μm/s. The identiﬁcation of positive mode MSMS
fragments was performed by matching the fragmentation
patterns of the compounds analyzed with previously reported
fragmentation pattern for PCs and PEs.38 The identiﬁcation of
negative mode MSMS fragments was mainly based on the mass
of fatty acid carboxylate fragments. For all features, the accurate
mass was compared to the measured mass and compounds. All
compounds with a mass diﬀerence of more than 25 ppm were
excluded. Whenever possible, the acquired spectra were also
compared to the MSMS fragmentation pattern provided in the
Metlin database (https://metlin.scripps.edu).
DESI-MS Data Analysis. Mass spectrometry imaging data
were imported into the Matlab (Mathworks Inc., Natick, MA,
USA) environment and processed using an in-house tool-
box.29,39 Regions within each sample were annotated as either
“control” or “lesion”. These annotated pixels across the sample
cohort were extracted and binned to 1 Da resolution over the
(phospholipid) m/z range 600−1000. Each spectrum was
normalized to its total intensity.
One-way analysis of variance (ANOVA) was performed
between control and lesion groups. False discovery rate (FDR)
correction was applied using the Benjamini−Hochberg−
Yekutieli (BHY) method with α = 0.05. Principal component
analysis (PCA) was used to identify trends in the data, and
maximum margin criterion linear discriminant analysis (MMC-
LDA) was used to classify control and lesion spectra. For
MMC-LDA, a 10-fold internal cross validation scheme was
employed. Accurate masses and annotations of signiﬁcant
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features were determined by reference to the tandem MS
experiments. Annotation of the top ten most diﬀerentiating
peaks for each group and ion mode was performed using the
Lipid Maps (http://www.lipidmaps.org/) and METLIN
(https://metlin.scripps.edu/index.php) databases and a mass
accuracy of 15 ppm.
Raman and DESI-MS Coregistration and Heterospec-
tral Analysis. The mouse samples analyzed by DESI (negative
mode) and Raman were coregistered using a ﬁducial marker-
based alignment. Four pairs of corresponding markers were
manually marked on each of the two images. An aﬃne
transformation was used to coregister the DESI image to match
the Raman image. Each of the individual DESI ion images was
resized and linearly interpolated using the imwarp function in
Matlab (Mathworks Inc., Natick, MA, USA). Following
coregistration, a single region spanning the corpus callosum
and “background” was marked, with these pixels from DESI and
Raman being unit vector normalized prior to correlation
analysis.40 Correlation coeﬃcients between DESI and Raman
variables were determined. Correlations with p > 0.05 were
discounted. Finally, we also performed a multivariate regression
analysis of the normalized Raman spectra against the individual
masses using a 3 component PLS regression with venetian blind
cross validation to estimate model complexity.
Data Availability. Supporting raw data is available at DOI:
https://doi.org/10.5281/zenodo.1064450.
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